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Streszczenie
Somatoliberyna (GHRH) jest głównym czynnikiem 
pobudzającym wydzielanie hormonu wzrostu (GH) 
i proliferację komórek somatotropowych, natomiast 
jej przewlekły wpływ na komórki przedniego płata 
przysadki nie jest tak jednoznaczny. Wiadomo, że u 
chorych z wyspiakiem trzustki wydzielającym GHRH 
dochodzi do rozwoju akromegalii i hiperplazji komórek 
przedniego płata przysadki. U myszy transgenicznych 
dla GHRH dochodzi natomiast do rozwoju gruczolaków 
somatotropowych. Celem naszej pracy była ocena 
wpływu przewlekłego podawania GHRH na aktywność 
wydzielniczą komórek somatotropowych, ich liczbę 
oraz proliferację komórek przedniego płata przysadki. 
Doświadczenie przeprowadzono na szczurach 
samcach szczepu Fischer 344 o masie ciała 200 ± 20 g. 
Zwierzęta podzielono na 2 grupy: grupa I – kontrola 
(13 zwierząt) otrzymywała rozpuszczalnik dla GHRH 
- 5% etanol w wodzie demineralizowanej; grupa II 
(10 zwierząt) otrzymywała GHRH (Growth Hormone 
Releasing Factor, fragment 1-29 amide) w dawce 5 
µg/dobę. Substancje były podawane przez miesiąc 
za pomocą pomp osmotycznych firmy ALZET, które 
wszczepiono zwierzętom podskórnie w okolicę grzbietu 
w znieczuleniu ketaminą. Po 4 tygodniach zwierzęta 
uśmiercono przez dekapitację. Od wszystkich zwierząt 
pobrano krew celem oznaczenia stężenia szczurzego GH 
(rGH) (metodą RIA). W preparatach mikroskopowych 
przysadek barwionych metodą tetrachromową Herlanta 
oceniano morfologię przysadek, a w preparatach 
barwionych immunohistochemicznie - odsetek komórek 
somatotropowych i proliferację komórkową (indeks 
PCNA). 
Wykazano, że przewlekłe podawanie GHRH powoduje 
znamienny wzrost średniego stężenia rGH w surowicy 
krwi zwierząt oraz odsetka komórek somatotropowych 
w przysadce, nie zmieniając wskaźnika proliferacji 
komórkowej w porównaniu z grupą kontrolną. 
Podsumowując, miesięczne podawanie GHRH nie 
indukuje rozwoju gruczolaków somatotropowych, 
powoduje natomiast wzrost stężenia GH w surowicy 
krwi zwierząt, co przynajmniej częściowo wydaje się 
zależeć od wzrostu odsetka komórek somatotropowych.
(Endokrynol Pol 2005; 6(56): 927-932)
Słowa kluczowe: przysadka, proliferacja, somatoliberyna, 
komórki somatotropowe
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Abstract
Growth Hormone-Releasing Hormone (GHRH) is 
the main factor, which regulates GH secretion and 
somatotrope proliferation. However, its chronic effect 
on anterior pituitary gland is still unknown. It is 
known that excessive GHRH secretion in patients with 
gastroenteropancreatic tumors secreting GHRH results 
in acromegaly and somatotrope hyperplasia. In mice 
transgenic for GHRH somatotrope tumors develop. Thus, 
the aim of this paper was to examine the effect of GHRH 
chronic administration on somatotrope secretion, their 
percentage and cell proliferation in anterior pituitary gland 
in rats. The experiment was performed on male Fischer 
344 rats weighing 200 ± 20 g. The animals were divided 
into two groups: group I – controls (13 rats) received 
solvent for GHRH (5% ethanol in demineralized water); 
group II (10 rats) received GHRH (Growth Hormone 
Releasing Factor, fragment 1-29 amide) at a dose of 5 µg/
day. The substances were given for 1 month via osmotic 
pump (ALZET), which were implanted subcutaneously in 
the dorsal region under ketamin anesthesia. After 4 weeks 
all rats were decapitated and the blood was collected. In 
the microscopic preparations of anterior pituitary gland 
the morphology of pituitary (Herlant staining) and the 
percentage of somatotrope cells and proliferation index 
based on PCNA staining were assessed. 
It was found that the chronic treatment with GHRH 
caused a statistically significant increase in serum rGH 
concentration and in percentage of somatotropes, but 
did not change proliferation index and did not induce 
pathological changes in the morphology of the anterior 
pituitary gland when compared to the control group.
Summing up, monthly GHRH administration did not 
induce somatotrope adenomas but it caused serum GH 
level elevation, what seems to depend partially on the 
increase of somatotrope number.
(Pol J Endocrinol 2005; 6(56): 927-932)
Key words: pituitary gland, proliferation, somatorelin, 
somatotrope
Aknowledgments
This work was supported by the statutory funds of Medical 
University of Łódź number 503-184-3 and 503-584-1.
Introduction
Somatorelin – GHRH (Growth Hormone Realising 
Hormone) is a 44 amino acid neurohormone stimu-
lating synthesis and secretion of growth hormone 
(GH) in the pituitary gland and is produced in 
hypothalamic nuclei and other tissues. It was 
isolated in 1982 by 2 independent groups of resear-
chers: Guillemin et al. [1] and Rivier et al. [2] 
from pancreatic islet-cell tumors causing acrome-
galy. The first isolation and structural characteri-
zation of somatorelin from human hypothalami 
was carried out by Ling et al. in 1984 [3]. Somato-
relin regulates not only the function of somatotro-
pes, but also their proliferation [4]. This hormone 
acts through its specific G-protein coupled receptor 
(GHRH-R), which activates the adenylyl cyclase to 
generate cAMP [5]. Beside GHRH, the secretion of 
growth hormone is also controlled by other factors 
like somatostatin, ghrelin and somatomedin C 
(IGF-I). Somatorelin stimulates cell proliferation 
in several non-pituitary tissues, both normal and 
neoplastic, acting indirectly trough GH and IGF-I 
and directly as an auto- and paracrine factor [6]. 
The same conclusions result from the studies with 
GHRH antagonists (in vitro and in vivo), which 
inhibit tumor growth through the a.m. mechanisms 
[7-9]. Recently many other functions of GHRH 
were suggested. This hormone is involved in sleep 
regulation, especially the non-REM phase [10]. The 
role of GHRH in the counteraction of aging is also 
discussed [11].
Although the number of publications concerning 
the effect of GHRH on somatotrope proliferation is 
limited, the experimental studies of animal models 
with genetically modified hypothalamo-pituitary 
GH axis provide some additional information. The 
animals with diminished production of GHRH (Tgr 
rat [12], TH-hGH mouse [13], Gsh-1 gene disrupted 
mouse [14], GHRHKO mouse [15]) and with 
impaired GHRH signaling (“little” (lit) mouse [16-
17], “dwarf” (dw) rat [18], CREB-mutant transgenic 
mouse [19]) are characterized by the hypoplastic 
pituitary caused by the decreased number of somato-
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tropes. Several mutations in the GHRH-R gene were 
also identified in children with growth retardation 
and reduced pituitary size observed in the MRI 
pictures, probably connected with hypoplasia of 
somatotropic cells [20-21]. On the other hand, the 
experiments with transgenic mouse overexpressing 
GHRH (metallothionein – human growth hormone-
releasing hormone (MT-hGRH) transgene) [22-26] 
and clinical observations in patients with ectopic 
GHRH secretion [27-33] give information about the 
chronic effect of supraphysiological level of endoge-
nous somatorelin. Hyperplasia of somatotropic cells 
or even somatotrope tumor development observed 
in a.m. studies suggest the role of somatorelin in the 
control of pituitary cell proliferation and pituitary 
tumorigenesis.
All these findings indicate the importance of 
GHRH not only in the proper development and 
function of pituitary, but also in pathogenesis of 
somatotrope adenoma.
However, some diagnostic difficulties, such as 
problems with distinction between hyperplastic 
and adenomatous changes and the lack of sufficient 
amount of material to examine, contribute to the 
problems with defining the role of GHRH and other 
hypothalamic factors in the pituitary adenoma 
formation. 
The effects of chronic GHRH administration 
in animals and humans remain still unknown. 
Therefore, the aim of this paper was to examine the 
chronic (monthly) effect of GHRH on somatotrope 
secretion, their percentage and cell proliferation in 
the anterior pituitary gland in rats.
Materials and methods
The experiment was performed on 50 male Fisher 
344 rats weighing 200 ±20 g. The animals were 
divided into 2 groups: group I – controls (C) (13 
rats) received solvent for GHRH (5% ethanol in 
demineralized water); group II (10 rats) received 
GHRH (Growth Hormone Releasing Factor, 
fragment 1-29, ICN Biomedicals Inc.) at a dose of 
5µg/day. The substances were given for 1 month 
via osmotic pumps (ALZET, model 2004), which 
were implanted subcutaneously in the dorsal region 
of rat under ketamin anesthesia (Ketanest; PARKE-
DAVIS; at a dose 120 mg/kg b.w. intraperitoneally). 
The model 2004 of Alzet pump is able to deliver the 
given dose of examined substance during 28 days.
After 4 weeks all rats were decapitated and 
the blood was collected to measure the serum rat 
GH (rGH) concentration using the Rat Growth 
Hormone (rGH) [125I] Biotrak Assay System with 
Magnetic Separation (Amersham Biosciences). The 
pituitaries were removed, fixed in Bouin-Holland’s 
solution, weighed and underwent the routine histo-
pathological procedure. The paraffin-embedded 
sections were stained according to tetrachrome 
Herlant’s technique to assess the gland morpho-
logy. The paraffin-embedded sections were also 
used for immunohistochemistry. The antibodies 
against rGH (Growth Hormone, Sheep Polyclonal 
Antibody, ICN Biomedicals Inc.) were applied to 
detect somatotropes and the antibody against Proli-
ferating Cell Nuclear Antigen (PCNA) (Mouse Anti-
Proliferating Cell Nuclear Antigen, PC10; DAKO) 
were used to evaluate proliferation. The sections 
with the primary antibodies were incubated for 
24 hours at the temperature of 4ºC. The primary 
antibodies for rGH were then detected using the 
appropriate biotinylated secondary antibodies. The 
immunoreaction was visualized by the using of the 
streptavidin-peroxidase complex (StreptABC/HRP, 
Dako) and 3, 3’-diaminobenzidine. The immunore-
action for PCNA was visualized using En Vision 
System AP (Dako). The number of somatotropes 
(GH-positive cells) was calculated per 400-500 
pituitary cells from randomly selected sections 
and was expressed in percentages. The number of 
PCNA-positive cells was calculated per 1000 cells of 
anterior pituitary and was expressed in promilles.
Results
The results were showed in Figures 1-4.
It was found that monthly administration of 
GHRH to rats caused a small, statistically insigni-
ficant, increase in body weight in comparison 
with the average body weight of animals in the 
control group (Fig. 1). In our experiment somato-
relin did not change the weight of pituitary gland 
(Fig. 2), but it caused an increase in mean rGH 
serum concentration compared to the control group 
(Fig. 3). However, it should be emphasized that the 
rGH serum concentration in the group treated with 
GHRH varied considerably from animal to animal 
(17.9 ng/ml - 169.69 ng/ml), while it did not occur 
in the control group (Table I).
Chronic administration of GHRH led to the 
increase in somatotrope percentage (Fig.4-6) without 
the enhancement of total proliferation index (based 
on PCNA staining) of the anterior pituitary gland 
(Fig.7). Only a small, statistically insignificant rise 
in the number of PCNA-positive cells was stated 
in the group treated with GHRH. There were not 
found any pathological changes in morphology of 
the anterior pituitary gland in the GHRH treated 
group except foci of increased vascularisation in 2 
of 10 pituitaries.
Discussion
To assess the chronic effect of GHRH on the somato-
trope secretion, their percentage and cell prolifera-
tion in anterior pituitary gland in rats, we applied 
the osmotic pump. The pumps assure an optimal 
way of chronic administration of the investigated 
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Fig. 5 Microphotograph of pituitary gland from the rat 
treated with GHRH immunostained for rGH. (x400)
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Fig.2 Effect of GHRH on rat pituitary weight (X ± SEM)
Fig. 2 Effect of GHRH on rat pituitary weight (X ± SEM)
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Fig. 7 Effect of GHRH on rat anterior pituitary cell proliferation (X ± SEM)
Fig. 7 Effect of GHRH on rat anterior pituitary cell 
proliferation (X ±SEM)
Fig. 6 Microphotograph of pituitary gland from the rat of 
control group immunostained for rGH. (x400)
substances. They were implanted subcutaneously 
in dorsal region and guaranteed a steady release 
of compounds, great repeatability of doses, which 
resulted in the constant level of the examined 
Effect of GHRH on rat anterior pituitary Motylewska E.
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substance in the blood and tissues. Such way of 
application is especially important in experiments 
with compounds of short plasma half-time such as 
GHRH (T1/2 for the 200ug dose is 7.6min) [34]. The 
use of osmotic pump eliminates the fluctuations of 
substance concentration in the body and reduces 
stress as compared to the typical multiple injections. 
It is well known that somatorelin enhances 
the synthesis and release of GH. However, to our 
knowledge its chronic effect has not been investi-
gated so far. Our findings indicate that the monthly 
administration of GHRH caused an increase of 
mean rGH serum concentration compared to the 
control group. However, it should be stressed that 
the rGH serum concentration in the group treated 
with GHRH varied considerably from animal to 
animal, which might be attributed to the process of 
desensitization.
Although the proliferative effect of GHRH on 
somatotropes is widely accepted, it has not often 
been under investigation. The mitogenic influence 
of somatorelin on cultured somatotropes was 
showed in an in vitro study using autoradiographic 
detection of [3H]thymidine uptake and immunohi-
stochemical identification of GH-producing cells. In 
this experiment somatorelin caused a substantial 
increase in the percentage of somatotropes labeled 
with [3H]thymidine compared to the control group 
and this effect seemed to be mediated by cAMP [4].
Other information about the proliferative effect 
of GHRH comes from observation of genetically 
modified animals. Mice transgenic for GHRH 
(metallothionein – human growth hormone-
releasing hormone (MT-hGRH) transgene) are a 
classical model for investigations of the chronic 
effect of supraphysiological level of somatore-
lin. These animals are characterized by greater 
body weight and enlargement of pituitary gland 
with hyperplasia of somato- and/or lacto-and/or 
somatolacto- and/or thyreotrophs [22-26]. It was 
found that longer, 9-24 months lasting exposure 
to the great concentration of endogenous GHRH 
could lead not only to their hyperplasia, but also to 
somatotrope adenoma formation [22-23]. However, 
the modest increase in GHRH expression, as occurs 
in GH receptor gene disrupted mice (GHR-/- mice), 
is sufficient only to expand the somatotrope popula-
tion but do not lead to the adenoma formation [24]. 
The appearance of adenoma preceded by somato-
trope hyperplasia in animals generated from 
cross-breeding MT-hGHRH transgenic mouse with 
GHR-/- mice proved that the proliferative effect of 
GHRH on somatotropes is direct and independent 
of GH and IGF-I action [24]. 
The observations of patients with disorders of 
GHRH secretion or action confirme its prolifera-
tive effect. Patients with ectopic GHRH secreting 
tumors developed somatotrope hyperplasia [27-30] 
and in a few cases [31-33] somatotrope adenomas. 
From 30% to 40% of somatotrope adenomas are 
caused by an activating mutation in alfa subunit of 
Gs protein coupled with GHRH-R, which supports 
the role of GHRH in the control of pituitary cell 
proliferation [35].
The data imply that the duration of exposure to 
GHRH as well as its plasma concentration determine 
the variety of changes observed in the pituitary. In 
our experiment, the monthly administration of 
somatorelin induced only a rise in the percentage of 
somatotropes (immunohistochemical method) with 
small, statistically insignificant enhancement of the 
total pituitary cell proliferation (PCNA index) and 
without adenoma formation. Enhancement of GH 
synthesis resulting in the more visible immunoreac-
tivity for GH could explain such result. It could also 
reflect the process of cytoredifferentation and trans-
formation of other cells into GH producing cells. 
The increased somatotrope proliferation, although 
not statistically significant, cannot be excluded as a 
possible cause of increase of their percentage. The 
lack of changes in the weight of pituitary glands 
could be connected with imprecise measurements.
Surprising observations in our experiment were 
some foci of increased vascularisation in 2 of 10 
pituitary glands in the group treated with GHRH. 
This result is the first mention in the literature concer-
ning proangiogenic effect of chronic administration 
of somatorelin. These changes would not be noticed 
if it were not for the paralelly carried out studies 
with the newly synthesized GHRH analogs, which 
enhanced the angiogenesis considerably (unpubli-
shed observation from our laboratory). The studies 
with GHRH antagonists carried out in our labora-
tory seem to be in agreement with our observations 
of proangiogenic action of somatorelin. The GHRH 
antagonists exert antiangiogenic properties at least 
partially through the inhibition of vascular endothe-
lial growth factor (VEGF) secretion and the suppres-
sion of endothelial cell proliferation [36]. It suggests 
an opposite proangiogenic action of GHRH. 
The observed proangiogenic effect should be 
confirmed in further studies using the anti-CD 31 
Tab. I r-GH serum concentration [ng/ml]
controls GHRH
9,42 45,22
14,25 169,69
5,18 69,64
11,65 37,78
19,17 34,17
7,86 89,15
6,66 68,17
10,27 31,89
6,64 17,9
5,57
16,75
mean 10,31 62,62
sd 4,69 45,99
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antibody in order to visualize immunohistochemi-
cally the endothelial cells in pituitary glands. 
Conclusions
To sum up, monthly administration of GHRH 
caused serum GH level elevation, which seems to 
depend partially on the increase of somatotrope 
number. The role of GHRH in pituitary adenoma 
formation remains still unclear.
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